Prominent biostatician will lead company’s research into novel clinical trial designs
SAN FRANCISCO–(BUSINESS WIRE)–#AI–Unlearn®, the only artificial intelligence (AI) company developing prognostic digital twins to run smaller, faster clinical trials, today announced that Arman Sabbaghi, Ph.D. has been appointed Head of Biostatistics Research. In this role, he will lead the company’s research and development activities to develop novel clinical trial applications that capitalize on the unique value of prognostic digital twins to reimagine the clinical trial for the 21st century.
“We are pleased to welcome Arman to the Unlearn team. With a deep background in the development of novel statistical methodologies, Bayesian data analysis, experimental design, and causal inference, his contributions will be essential to our regulatory progress and the continued expansion of our patent portfolio,” said David Miller, Chief Science Officer at Unlearn. “On behalf of the entire team, we are looking forward to Arman’s leadership and contributions to helping our partners improve the efficiency of their clinical trials.”
Arman joins Unlearn from Purdue University where he was most recently an Associate Member in the Regenstrief Center for Healthcare Engineering, Associate Director of the Statistical Consulting Service, and an Associate Professor of Statistics. At Purdue, his research focused on the development of new causal inference methodologies for analyzing observational data and clinical trials plagued by intercurrent events, the creation of mathematical tools for characterizing broad classes of experimental designs, and the development of efficient and interpretable machine learning algorithms for quality control in advanced manufacturing. Arman became an Elected Member of the International Statistical Institute in December 2020, and was a Visiting Scholar in the Department of Statistics at the University of California, Berkeley during the 2021 – 2022 academic year. Arman earned a Masters and Ph.D. in Statistics from Harvard University and BS in Mathematics (with Honors) and Mathematical Statistics from Purdue University.
“Statistics and data science are rapidly transforming the biomedical sciences. I am truly excited to work alongside the talented team at Unlearn to pioneer cutting-edge methodologies and algorithms that further advance the company’s mission – enabling more efficient clinical trials in the service of delivering better medicines to patients faster,” said Arman.
Founded in 2017, Unlearn.AI brings together a world-class team of experts across pharma, physics, machine learning, and business who share a vision of pioneering AI to eliminate trial and error in medicine. Unlearn is the only company creating TwinRCTs™, which combine AI, prognostic digital twins, and novel statistical methods to run clinical trials requiring fewer patients in the control arm. Unlearn’s technology is used by leading global pharmaceutical companies, including Merck KGaA, Darmstadt, Germany, and has been published in conference abstracts and scientific journals, including Scientific Reports – Nature and The International Journal of Biostatistics. The European Medicines Agency qualifies Unlearn’s PROCOVA™ procedure, which provides the regulatory framework for the application of TwinRCTs to Phase 2 and 3 clinical trials. For more information, please visit https://www.unlearn.ai or follow @UnlearnAI on Twitter, @unlearn-ai on LinkedIn.